Page last updated: 2024-10-21

3-methoxytyramine and Dyskinesia, Medication-Induced

3-methoxytyramine has been researched along with Dyskinesia, Medication-Induced in 2 studies

3-methoxytyramine: RN given refers to parent cpd
3-methoxytyramine : A monomethoxybenzene that is dopamine in which the hydroxy group at position 3 is replaced by a methoxy group. It is a metabolite of the neurotransmitter dopamine and considered a potential biomarker of pheochromocytomas and paragangliomas.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Morin, N1
Morissette, M1
Grégoire, L1
Di Paolo, T1
Ananth, J1

Reviews

1 review available for 3-methoxytyramine and Dyskinesia, Medication-Induced

ArticleYear
Current psychopathological theories of tardive dyskinesia and their implications for future research.
    Neuropsychobiology, 1982, Volume: 8, Issue:4

    Topics: Acetylcholine; Adult; Aged; Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced

1982

Other Studies

1 other study available for 3-methoxytyramine and Dyskinesia, Medication-Induced

ArticleYear
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Progress in neuro-psychopharmacology & biological psychiatry, 2015, Jan-02, Volume: 56

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide;

2015